Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients

X Charmetant, M Espi, I Benotmane… - Science Translational …, 2022 - science.org
X Charmetant, M Espi, I Benotmane, V Barateau, F Heibel, F Buron, G Gautier-Vargas…
Science Translational Medicine, 2022science.org
Transplant recipients, who receive therapeutic immunosuppression to prevent graft
rejection, are characterized by high coronavirus disease 2019 (COVID-19)–related mortality
and defective response to vaccines. We observed that previous infection with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), but not the standard two-dose regimen
of vaccination, provided protection against symptomatic COVID-19 in kidney transplant
recipients. We therefore compared the cellular and humoral immune responses of these two …
Transplant recipients, who receive therapeutic immunosuppression to prevent graft rejection, are characterized by high coronavirus disease 2019 (COVID-19)–related mortality and defective response to vaccines. We observed that previous infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but not the standard two-dose regimen of vaccination, provided protection against symptomatic COVID-19 in kidney transplant recipients. We therefore compared the cellular and humoral immune responses of these two groups of patients. Neutralizing anti–receptor-binding domain (RBD) immunoglobulin G (IgG) antibodies were identified as the primary correlate of protection for transplant recipients. Analysis of virus-specific B and T cell responses suggested that the generation of neutralizing anti-RBD IgG may have depended on cognate T-B cell interactions that took place in germinal center, potentially acting as a limiting checkpoint. High-dose mycophenolate mofetil, an immunosuppressive drug, was associated with fewer antigen-specific B and T follicular helper (TFH) cells after vaccination; this was not observed in patients recently infected with SARS-CoV-2. Last, we observed that, in two independent prospective cohorts, administration of a third dose of SARS-CoV-2 mRNA vaccine restored neutralizing titers of anti-RBD IgG in about 40% of individuals who had not previously responded to two doses of vaccine. Together, these findings suggest that a third dose of SARS-CoV-2 mRNA vaccine improves the RBD-specific responses of transplant patients treated with immunosuppressive drugs.
AAAS